Please login to the form below

Not currently logged in
Email:
Password:

Established Product Management

Sponsored by

Back to Results


Finalist

Optimising Outcomes

By: Celgene UK


Summary of work

Multiple myeloma is a cancer arising from plasma cells, characterised by periods of relapse and ultimately death with 5,500 new cases in the UK each year. Less than 50% of patients survive to five years.

It is imperative that myeloma treatment is fully optimised as the benefit of treatment directly correlates with increased overall survival.

REVLIMID® and IMNOVID® are licensed for the treatment of multiple myeloma. NICE recommends REVLIMID® in patients who have failed two prior therapies. Earlier use of REVLIMID® and IMNOVID® was funded via the Cancer Drugs Fund (CDF) prior to November 2015.

Withdrawal of CDF funding for IMNOVID® resulted in very few funded licensed treatment options for relapsed refractory patients failing REVLIMID®. It became critical to ensure that patients were successfully treated with REVLIMID® until disease progression.

A campaign to optimise treatment outcomes with REVLIMID® was launched with an immediate focus on identifying patients relapsing on REVLIMID® who would benefit from IMNOVID® prior to CDF delisting and a longer-term focus on maintaining patients on REVLIMID® until disease progression through better side-effect management.

Patient retention increased quickly with a 6% improvement by December 2015, equivalent to over 166 years of additional life for myeloma patients in the UK.

Judges' comments

This work produced great data on treatment dynamics and used it to get results. Celgene showed a detailed understanding of treatment continuation dynamics and the back-to-basics focus achieved results in a short period of time.


Winner

Fresubin Big Deal - By: Fresenius Kabi
With support from: Havas Life Medicom


Highly commended

75 Not Out - By: Celgene UK


Highly commended

Remaining Relevant in MS - By: Teva Pharmaceuticals Europe
With support from: VCCP Health


Finalists

Optimising Outcomes - By: Celgene UK

Improving Access to SIRT - By: Sirtex
With support from: 90TEN and Denova Strategy